CKD Progression and Renoprotection
On this page
Direct answer
CKD progression is the steady fall in eGFR driven by glomerular hypertension, proteinuria and ongoing injury, and renoprotection aims to slow it. The core measures are blood pressure control, RAAS blockade for albuminuria, SGLT2 inhibitors and, in type 2 diabetes with CKD, finerenone. Proteinuria is the modifiable marker most examiners expect candidates to name first.
What you must remember
- Proteinuria as driver: the strongest modifiable predictor of progression, so reducing urinary albumin or protein is the central renoprotective goal.
- Blood pressure target: KDIGO suggests a systolic target below 120 mmHg where tolerated, measured under standardised conditions.
- RAAS blockade: an ACE inhibitor or ARB at the maximum tolerated dose for albuminuria, with creatinine and potassium rechecked after starting.
- Never combine: ACE inhibitor with ARB adds hyperkalaemia and acute kidney injury risk without renal benefit.
- SGLT2 inhibitors: dapagliflozin and empagliflozin slow eGFR decline in CKD in diabetic and non-diabetic patients, while canagliflozin has trial evidence in diabetic kidney disease.
- Finerenone: a non-steroidal mineralocorticoid receptor antagonist for type 2 diabetes with CKD and albuminuria, started once potassium is normal.
- Diet and habits: sodium restriction to about 2 g per day, smoking cessation, glycaemic control, and avoidance of NSAIDs and other nephrotoxins.
A stepwise approach to slowing CKD progression
Renoprotection is built in layers, and each drug is usually added once the previous step is in place. The sequence below mirrors how a nephrologist plans therapy for a patient with stable CKD.
-
Quantify the risk. Measure eGFR and urine albumin-creatinine ratio, because eGFR and albuminuria category together stage the risk of progression.
-
Control blood pressure. Aim for the systolic target while watching for orthostatic symptoms, particularly in older patients.
-
Block the renin-angiotensin system. Start an ACE inhibitor or ARB and titrate to the maximum tolerated dose. A creatinine rise of up to about 30 per cent is generally accepted, and larger rises need review for volume depletion or renal artery stenosis.
-
Add an SGLT2 inhibitor. Start when the eGFR threshold for the chosen drug is met. Expect a small early eGFR dip, which is haemodynamic and not a reason to stop.
-
Consider finerenone. In type 2 diabetes with CKD and albuminuria, add finerenone once potassium is normal, and recheck potassium at planned intervals.
-
Address complications. Correct anaemia, metabolic acidosis and hyperphosphataemia, and plan early for kidney replacement as eGFR falls.
Where the exam tries to catch you
Renoprotection questions usually test the drug combination, the safety check or the direction of an expected change.
- Trap: combining an ACE inhibitor with an ARB for extra proteinuria reduction. Correct: dual RAAS blockade raises hyperkalaemia and AKI risk without benefit, so only one class is used.
- Trap: stopping an SGLT2 inhibitor for the early eGFR dip. Correct: the initial fall is haemodynamic and usually settles, and the long-term renal benefit is the reason to continue.
- Trap: choosing a calcium channel blocker as first-line for proteinuric CKD. Correct: ACE inhibitors or ARBs are preferred when albuminuria is present, and other agents are added to reach the blood pressure target.
Frequently asked questions
What rise in serum creatinine is acceptable after starting an ACE inhibitor or ARB in CKD?
A rise of up to about 30 per cent over baseline serum creatinine is generally accepted after starting an ACE inhibitor or ARB in chronic kidney disease. Larger rises should prompt a check for volume depletion or renal artery stenosis before the dose is changed. Serum potassium is monitored alongside creatinine during this period.
Which SGLT2 inhibitors have trial evidence for renal protection in CKD?
Dapagliflozin and empagliflozin have trial evidence for slowing CKD progression in both diabetic and non-diabetic patients. Canagliflozin has evidence in diabetic kidney disease. Renoprotection is an established benefit of these drugs, independent of their glucose-lowering effect.
Why is finerenone preferred over a steroidal mineralocorticoid antagonist in diabetic kidney disease?
Finerenone is a non-steroidal antagonist that lowers albuminuria and cardiovascular events in type 2 diabetes with CKD and albuminuria, and its hormonal side effects are less common than with spironolactone. Hyperkalaemia remains the key risk of finerenone, so potassium must be checked during treatment. The drug is used only with the indications its label allows.
What eGFR is needed before starting an SGLT2 inhibitor for chronic kidney disease?
Initiation thresholds for SGLT2 inhibitors are drug-specific, and many labels allow starting at an eGFR of about 20 to 25 mL/min per 1.73 m2. Renoprotection can continue below the starting threshold once the drug is established. The product label should be checked for the exact figure used in practice.